NEWS Oncoscience signs contract with YM Biosciences Inc. ByOncoscience 15. November 200317. July 2025 Read the press release Download: >> press_release_YM_Biosciences (.pdf 28kB) Ähnliche Beiträge
NEWS Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer ByOncoscience 28. May 202217. July 2025
Allgemein | NEWS Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab. ByOncoscience 6. November 202017. July 2025
NEWS Oncoscience AG announced a change in the board of directors ByOncoscience 15. October 200417. July 2025
NEWS YM BioSciences’ EGFr antibody receives EU orphan drug designation through Oncoscience AG, its European partner ByOncoscience 10. August 200417. July 2025
NEWS Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009 ByOncoscience 9. October 200917. July 2025
